Publisher
Springer Nature Singapore
Reference12 articles.
1. Arrondeau, J., Gan, H. K., Razak, A. R., Paoletti, X., & Le Tourneau, C. (2010). Development of anti-cancer drugs. Discovery Medicine, 10(53), 355–362.
2. Baghdadi, R., & Laffler, M. J. (2013). The next phase in oncology: FDA’s Pazdur has new vision for drug development. The Pink Sheet.
3. Chen, T. T. (1997). Optimal three-stage designs for phase II cancer clinical trials. Statistics in Medicine, 16(23), 2701–2711.
4. Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., ... & Verweij, J. (2009). New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer, 45(2), 228–247.
5. Grayling, M. J., & Mander, A. P. (2020). Two-stage single-arm trials are rarely reported adequately. arXiv preprint arXiv:2007.04168